Piramal Enterprises Ltd on Monday said its wholly-owned subsidiary Piramal Critical Care based in the UK has entered into an agreement to acquire five anaesthesia and pain management injectable products from Janssen Pharmaceutica NV, in an all-cash deal for an upfront consideration of $155 million, and up to an additional $20 million.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
